Department of Ophthalmology, Faculty of Medicine, Selçuk University, Konya, Turkey.
Acta Ophthalmol. 2011 Mar;89(2):138-42. doi: 10.1111/j.1755-3768.2009.01656.x.
This study aimed to observe changes in anterior chamber parameters and the course of intraocular pressure (IOP) after injection of 0.1 ml intravitreal triamcinolone acetonide (TA) and to determine differences between phakic and pseudophakic eyes without vitreous reflux.
A prospective observational clinical trial was conducted with 89 patients who received an intravitreal injection of TA and did not display vitreous reflux. Intraocular pressure measurements were made before injection and at 3, 10, 20, 30 and 40 mins after injection. Pentacam measurements were made before injection and at 5, 15, 30 and 45 mins after injection.
Anterior chamber depth (ACD) and anterior chamber volume (ACV) were significantly greater in pseudophakic eyes than in phakic eyes at all measurement time-points (p < 0.001). There was a decrease in both ACD and ACV at 5 mins after injection, and a gradual increase to normal values was observed at 15, 30 and 45 mins after injection in all study eyes. Compared with pre-injection measurements, changes in ACD and ACV were statistically significant at each time-point in both phakic and pseudophakic eyes (p < 0.001). A significant increase in IOP within 3 mins of injection was observed in both groups and a more rapid decrease 10 mins after injection was observed in pseudophakic eyes. The differences in IOP between phakic and pseudophakic eyes at all measurement time-points, except baseline and 3 mins after injection, were statistically significant (p < 0.001). Intraocular pressure < 30 mmHg and < 24 mmHg was recorded in all pseudophakic eyes at 10 and 20 mins after intravitreal injection, respectively.
Following intravitreal injection of 0.1 ml TA, without vitreous reflux, IOP decreased to safe levels more quickly in pseudophakic eyes than in phakic eyes. Although there were more pronounced changes in anterior chamber parameters in pseudophakic eyes, these changes were reversible without any residual clinical significance.
本研究旨在观察玻璃体无反流的情况下，0.1ml 玻璃体内曲安奈德（TA）注射后前房参数的变化和眼压（IOP）的变化过程，并确定有晶状体眼和无晶状体眼之间的差异。
对 89 例接受玻璃体内 TA 注射且无玻璃体反流的患者进行前瞻性观察性临床试验。注射前及注射后 3、10、20、30 和 40 分钟进行眼压测量。注射前及注射后 5、15、30 和 45 分钟进行 Pentacam 测量。
在所有测量时间点，人工晶状体眼的前房深度（ACD）和前房容积（ACV）均显著大于晶状体眼（p<0.001）。注射后 5 分钟时，ACD 和 ACV 均下降，所有研究眼在注射后 15、30 和 45 分钟时逐渐恢复正常。与注射前相比，在晶状体眼和人工晶状体眼中，ACD 和 ACV 在各个时间点的变化均有统计学意义（p<0.001）。两组注射后 3 分钟内眼压均显著升高，10 分钟后人工晶状体眼眼压下降较快。除基线和注射后 3 分钟外，在所有测量时间点，晶状体眼和人工晶状体眼之间的眼压差异均有统计学意义（p<0.001）。玻璃体内注射后 10 和 20 分钟，所有人工晶状体眼的眼压均<30mmHg 和<24mmHg。
玻璃体无反流的情况下，0.1ml 玻璃体内 TA 注射后，人工晶状体眼的 IOP 下降速度快于晶状体眼，达到安全水平。尽管人工晶状体眼的前房参数变化更为明显，但这些变化是可逆的，无任何残留的临床意义。
